The coronavirus pandemic has been bad news for nearly every type of asset class in 2020. On the flip side, this indiscriminate wave of selling has undoubtedly created some amazing buying opportunities for long-term investors. Biotech stocks, for instance, were particularly hard hit by the market's "man with a hammer" behavior over the past two weeks.
What's noteworthy about the biotech space is that these companies should prove to be largely immune to any economic downturn. People aren't going to stop taking their prescription medicines. after all. What's more, some biotechs are already playing a critical role in the battle against the COVID-19 illness by accelerating the development of novel medicines and vaccines. In short, opportunity knocks for those brave souls willing to buy biotechs in this volatile and exceedingly moody market.
Image source: Getty Images.